Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?

Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?

(2011) V. G. Athyros et al.   CURRENT PHARMACEUTICAL DESIGN

The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

(2010) Hyohun Park et al.   CLINICA CHIMICA ACTA

Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome

(2010) Diego Lucero et al.   CLINICA CHIMICA ACTA

The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population

(2010) Chia-Hung Chiang et al.   CLINICAL BIOCHEMISTRY

Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years

(2010) Eirini Lioudaki et al.   Current Vascular Pharmacology

Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?

(2010) Mohamed H. Ahmed et al.   DRUG DISCOVERY TODAY

Lipid-lowering agents and new onset diabetes mellitus

(2010) Vasilios G Athyros et al.   EXPERT OPINION ON PHARMACOTHERAPY

Advancing therapy for hypercholesterolemia

(2010) Konstantinos Toutouzas et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of 1-O-hexyl-2,3,5-trimethylhydroquinone on carbon tetrachloride-induced hepatic cirrhosis in rats

(2010) Jun An et al.   HEPATOLOGY RESEARCH

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease

(2010) Hyohun Park et al.   JOURNAL OF GASTROENTEROLOGY

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

(2010) Vasilios G Athyros et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)

(2009) Rafeeq Ali et al.   ANNALS OF MEDICINE

Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS)

(2009) Thozhukat Sathyapalan et al.   CLINICAL ENDOCRINOLOGY

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis

(2008) Giovanni Musso et al.   ANNALS OF MEDICINE

Do we need to consider inflammatory markers when we treat atherosclerotic disease?

(2008) Vasilios G. Athyros et al.   ATHEROSCLEROSIS

The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects

(2008) Ki Chul Sung et al.   ATHEROSCLEROSIS

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

(2008) Raj Vuppalanchi et al.   HEPATOLOGY

A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia

(2008) P. Matafome et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic association of atorvastatin and insulin in cardiac ischemia: Study in a model of type 2 diabetes with hyperlipidemia

(2008) P MATAFOME et al.   PHARMACOLOGICAL RESEARCH

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

(2008) Feng-Shang Zhu et al.   WORLD JOURNAL OF GASTROENTEROLOGY